{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:08:11Z","timestamp":1781762891876,"version":"3.54.5"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Adv Skin Wound Care"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To summarize clinical outcomes of paradoxical pyoderma gangrenosum (PG) onset in patients on biologic therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The authors conducted MEDLINE and EMBASE searches using PRISMA guidelines to include 57 patients (23 reports).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Of the included patients, 71.9% (n = 41\/57) noted PG onset after initiating rituximab, 21.1% (n = 12\/57) noted tumor necrosis factor \u03b1 (TNF-\u03b1) inhibitors, 5.3% (n = 3\/57) reported interleukin 17A inhibitors, and 1.8% (n = 1\/57) reported cytotoxic T-lymphocyte-associated protein 4 antibodies. The majority of patients (94.3%) discontinued biologic use. The most common medications used to resolve rituximab-associated PG were intravenous immunoglobulins, oral corticosteroids, and antibiotics, with an average resolution time of 3.3 months. Complete resolution of PG in TNF-\u03b1-associated cases occurred within an average of 2.2 months after switching to another TNF-\u03b1 inhibitor (n = 1), an interleukin 12\/23 inhibitor (n = 2), or treatment with systemic corticosteroids and cyclosporine (n = 3), systemic corticosteroids alone (n = 1), or cyclosporine alone (n = 1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS<\/jats:title>\n            <jats:p>Further investigations are warranted to determine whether PG onset is associated with underlying comorbidities, the use of biologic agents, or a synergistic effect. Nevertheless, PG may develop in patients on rituximab or TNF-\u03b1 inhibitors, suggesting the need to monitor and treat such adverse effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/01.asw.0000820252.96869.8e","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T11:01:48Z","timestamp":1647428508000},"page":"454-460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review"],"prefix":"10.1097","volume":"35","author":[{"given":"Yuliya","family":"Lytvyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalad","family":"Maliyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskaan","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"bib1-20250615","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-2-19","article-title":"Pyoderma gangrenosum\u2014a review","volume":"2","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"bib2-20250615","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjd.17347","article-title":"Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study","volume":"180","year":"2019","journal-title":"Br J Dermatol"},{"key":"bib3-20250615","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12394","article-title":"Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome","volume":"178","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"bib4-20250615","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","article-title":"Drug-induced pyoderma gangrenosum: a review","volume":"19","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"bib5-20250615","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","year":"2009","journal-title":"PLoS Med"},{"key":"bib7-20250615","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"bib8-20250615","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"bib9-20250615","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/LGT.0b013e3181eb30ff","article-title":"Superficial granulomatous pyoderma of the vulva in a patient receiving maintenance rituximab (MabThera) for lymphoma","volume":"15","year":"2011","journal-title":"J Low Genit Tract Dis"},{"key":"bib10-20250615","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/LGT.0000000000000043","article-title":"Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy","volume":"19","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"bib11-20250615","first-page":"478","article-title":"Rituximab causing deep ulcerative suppurative vaginitis\/pyoderma gangrenosum","volume":"17","year":"2015","journal-title":"Curr Infect Dis Rep"},{"key":"bib12-20250615","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/03009742.2016.1241298","article-title":"Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin","volume":"46","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"bib13-20250615","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jdcr.2018.09.003","article-title":"A case of rituximab-induced pyoderma gangrenosum","volume":"4","year":"2018","journal-title":"JAAD Case Rep"},{"key":"bib14-20250615","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jdcr.2018.09.001","article-title":"Vulvovaginal pyoderma gangrenosum in association with rituximab","volume":"4","year":"2018","journal-title":"JAAD Case Rep"},{"key":"bib15-20250615","first-page":"e13221","article-title":"Pyoderma gangrenosum adverse event with rituximab use: a postmarketing pharmacovigilance analysis","volume":"33","year":"2020","journal-title":"Dermatol Ther"},{"key":"bib16-20250615","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s10067-007-0733-8","article-title":"Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis","volume":"26","year":"2007","journal-title":"Clin Rheumatol"},{"key":"bib17-20250615","first-page":"817","article-title":"Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?","volume":"144","year":"2008","journal-title":"Arch Dermatol"},{"key":"bib18-20250615","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2340\/00015555-0777","article-title":"Paradoxical reactions to targeted biological treatments: away to treat and trigger?","volume":"90","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"bib19-20250615","first-page":"20","article-title":"Development of pyoderma gangrenosum during therapy with infliximab","volume":"3","year":"2009","journal-title":"J Dermatol Case Rep"},{"key":"bib20-20250615","first-page":"447","article-title":"Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis","volume":"11","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"bib21-20250615","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1684\/ejd.2015.2526","article-title":"Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab","volume":"25","year":"2015","journal-title":"Eur J Dermatol"},{"key":"bib22-20250615","first-page":"e71","article-title":"Triple paradoxical reaction due to adalimumab","volume":"31","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"bib23-20250615","first-page":"e270","article-title":"Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab","volume":"58","year":"2017","journal-title":"Australas J Dermatol"},{"key":"bib24-20250615","first-page":"1139","article-title":"Paradoxical uveitis and pyoderma gangrenosum in a patient with psoriatic arthritis under infliximab treatment","volume":"16","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"bib25-20250615","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","article-title":"Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab","volume":"38","year":"2018","journal-title":"Rheumatol Int"},{"key":"bib26-20250615","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/ijdvl.IJDVL_277_18","article-title":"Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: a paradoxical reaction","volume":"85","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"bib27-20250615","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13555-020-00398-4","article-title":"Paradoxical skin reaction to certolizumab, an overlap of pyoderma gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review","volume":"10","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"bib28-20250615","first-page":"e108","article-title":"Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab","volume":"46","year":"2019","journal-title":"J Dermatol"},{"key":"bib29-20250615","first-page":"e406","article-title":"First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab","volume":"33","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"bib30-20250615","first-page":"e13161","article-title":"Pyoderma gangrenosum induced by secukinumab\u2014a late paradoxical drug reaction","volume":"33","year":"2020","journal-title":"Dermatol Ther"},{"key":"bib31-20250615","first-page":"822","article-title":"A case of pyoderma gangrenosum in a patient with rheumatoid arthritis treated with abatacept","volume":"96","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"bib32-20250615","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jcpt.12198","article-title":"Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report","volume":"39","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"bib33-20250615","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy\u2014rare but there!","volume":"50","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"bib34-20250615","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","article-title":"Pyoderma gangrenosum: a review of pathogenesis and treatment","volume":"14","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"bib35-20250615","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib36-20250615","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood-2012-07-445007","article-title":"Intravenous immunoglobulin (IVIG) inhibits CD8 cytotoxic T-cell activation","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib37-20250615","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2008","article-title":"Effective strategies for the management of pyoderma gangrenosum: a comprehensive review","volume":"95","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"bib38-20250615","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/ced.12393","article-title":"Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis","volume":"39","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"bib39-20250615","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ddg.13173","article-title":"Treatment options for pyoderma gangrenosum","volume":"15","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"bib40-20250615","first-page":"752","article-title":"Clinical management of paradoxical psoriasiform reactions during TNF-alpha therapy","volume":"105","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"bib41-20250615","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/1744666X.2014.866038","article-title":"Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases","volume":"10","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"bib42-20250615","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing TH1 cells and IL-17A\/IL-22-expressing TH17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","year":"2014","journal-title":"Gut"},{"key":"bib43-20250615","doi-asserted-by":"crossref","first-page":"44189","DOI":"10.1038\/srep44189","article-title":"Endogenous TNF\u03b1 orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation","volume":"7","year":"2017","journal-title":"Sci Rep"},{"key":"bib44-20250615","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","year":"2019","journal-title":"Front Pharmacol"},{"key":"bib45-20250615","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","year":"2011","journal-title":"Arch Dermatol"},{"key":"bib46-20250615","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","year":"2016","journal-title":"RMD Open"},{"key":"bib47-20250615","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases","volume":"54","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"bib48-20250615","first-page":"e325","article-title":"Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis","volume":"45","year":"2018","journal-title":"J Dermatol"},{"key":"bib49-20250615","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10875-011-9527-5","article-title":"CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis","volume":"31","year":"2011","journal-title":"J Clin Immunol"},{"key":"bib50-20250615","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.4049\/jimmunol.172.5.2778","article-title":"CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells","volume":"172","year":"2004","journal-title":"J Immunol"},{"key":"bib51-20250615","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/72323","article-title":"Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population","volume":"6","year":"2000","journal-title":"Nat Med"},{"key":"bib52-20250615","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/ajcp\/80.3.396","article-title":"T helper-suppressor cell imbalance in pyoderma gangrenosum, with relapsing polychondritis and corneal keratolysis","volume":"80","year":"1983","journal-title":"Am J Clin Pathol"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.ASW.0000820252.96869.8e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:06:02Z","timestamp":1750021562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.ASW.0000820252.96869.8e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/01.asw.0000820252.96869.8e","relation":{},"ISSN":["1538-8654","1527-7941"],"issn-type":[{"value":"1538-8654","type":"electronic"},{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}